Imatinib vs Nivolumab
Imatinib vs Nivolumab: Overview
This comparison examines the pharmacological differences between Imatinib and Nivolumab.
Mechanism of Action
Imatinib: Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Imatinib — 18 hours; Nivolumab — 27 days.
Chemical Properties
Molecular Formula: Imatinib — C29H31N7O.
Molecular Weight: Imatinib — 493.6030 g/mol.
Type: Imatinib — Small molecule; Nivolumab — Antibody.